| CAS NO: | 1463459-96-2 |
| 生物活性 | Ascrinvacumab (PF-03446962) is a humanIgG2monoclonal antibody targetsALK-1. Ascrinvacumab shows binding efficiency with humanALK1with aKdvalue of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC)[1]. |
| 体外研究 (In Vitro) | Ascrinvacumab 与细胞人 ALK1 结合，Kd值为 7 nm[1]。Ascrinvacumab (30 分钟) 阻断 BMP9 和 FCS 诱导的应答，缓解 BMP9 诱导的 Smad1 磷酸化强度和持续时间[1]。Ascrinvacumab (0.01-10 μg/mL; 2 h) 抑制 BMP9 结合到 ALK1[1]。Ascrinvacumab (40 μg/mL; 2 h) 有效抑制人脐静脉内皮细胞 (HUVECs) 的内皮萌发[1]。 |
| 体内研究 (In Vivo) | Ascrinvacumab 联合贝伐单抗 (bevacizumab; anti-VEGF) 可降低人血管密度，提高抗肿瘤疗效在小鼠嵌合体肿瘤模型中[1]。 |
| CAS 号 | 1463459-96-2 |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
| 维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |